22 employees
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors.
2019
$45M
from 4 investors over 4 rounds
Avenge Bio raised $45M on January 5, 2022
Investors: Perceptive Advisors, Pappas Capital and Longitude Capital
Avenge Bio raised undisclosed on March 30, 2020
Investors: Longitude Capital